Why the Fisher & Paykel Healthcare (ASX:FPH) share price is sinking 6% today

This healthcare share is having a bad day…

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fisher & Paykel Healthcare's shares are sinking on Wednesday morning
  • Investors have responded negatively to its sales guidance update for FY 2022
  • Fisher & Paykel Healthcare also warned that freight costs are hurting margins

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is under pressure on Wednesday.

In morning trade, the medical device company's shares are down 6% to $24.20.

Why is the Fisher & Paykel Healthcare share price sinking?

Investors have been selling down the Fisher & Paykel Healthcare share price this morning following the release of a trading update out of the company.

According to the release, with the end of its financial year rapidly approaching, management now has a good idea of the revenue it will generate in FY 2022.

Based on current exchange rates, Fisher & Paykel Healthcare expects full year operating revenue for the 12 months ending 31 March to be in the range of NZ$1.675 billion to NZ$1.70 billion.

This represents a 13.7% to 15% decline year on year from NZ$1.97 billion in FY 2021.

Based on this, there has been a marked softening of its performance during the second half, as Fisher & Paykel Healthcare's half year operating revenue was only down 2% over the prior corresponding period.

What's happening?

Management explained that its performance has been impacted by softening demand in the hospital consumables segment due to the Omicron variant causing lower respiratory intervention requirements and a mild flu season in the Northern Hemisphere.

Fisher & Paykel Healthcare's Managing Director and Chief Executive Officer, Lewis Gradon, said: "Our second half hospital consumables revenue is currently tracking to be similar to the hospital consumables revenue that we reported in the first half of the 2022 financial year. This is consistent with reports of the increasing prevalence of the Omicron variant over the last two months and its associated lower respiratory intervention requirements, as well as a relatively mild flu season in the Northern Hemisphere."

"In our Homecare product group, growth in sales of our OSA masks is currently tracking above our first half growth rate despite supply constraints of treatment hardware in the market," he added.

Also putting pressure on the Fisher & Paykel Healthcare share price is news that its margins have been impacted by higher freight costs.

Mr Gradon said: "Freight rates remain elevated and for the 2022 financial year are expected to impact our long-term gross margin target of 65% by approximately 250 basis points."

Nevertheless, the Chief Executive Officer remains positive on the long term future of the company.

He concluded: "Regardless of how COVID-19 effects unfold over the short term, we are confident our business is well-placed to contribute to a positive change in clinical practice and improving outcomes for respiratory patients in general over the long term."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Healthcare Shares

Broker tips big gains and yields from NIB shares

Goldman Sachs is saying good things about this health insurance provider.

Read more »

A man with grahpics of robot arms, indicating a share price movement in ASX robotics and tech companies
Healthcare Shares

Up 784% in 5 years, why this ASX 200 healthcare share has a 'clear pathway' for growth in 2024

The ASX 200 stock has been a standout performer within the healthcare sector.

Read more »